Nuwellis Presents New Real-World Data Supporting Aquadex Ultrafiltration For Complex AKI Fluid Management At ASN Kidney Week

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today announced the presentation of new real-world data from New York City's Lenox Hill Hospital at the 2025 American Society of Nephrology (ASN) Kidney Week, reinforcing the versatility of Aquadex® ultrafiltration therapy in patients with acute kidney injury (AKI) and complex fluid management needs.

The retrospective analysis, titled "Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience" (Presentation #FR-PO0590), reviewed 69 cases treated with Aquadex between 2018 and 2024. The study demonstrated effective and predictable fluid removal in patients with multiple underlying conditions—ranging from oliguric AKI and post-cardiac-surgery volume overload to pre-operative optimization in end-stage renal disease.

The analysis found that patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among those on vasopressor support.